Latest news

• Boehringer pulls faldaprevir and exits hepatitis C market

  Boehringer pulls faldaprevir and exits hepatitis C market. Unable to challenge all-oral options from Gilead and others. ... Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus ( HCV) therapies and has discontinued

• Boehringer's faldaprevir set for rapid review in Europe

  Boehringer's faldaprevir set for rapid review in Europe. More competition in emerging hepatitis C market. ... Boehringer Ingelheim's new hepatitis C virus ( HCV) therapy faldaprevir could be on the market in the EU as early as the second half of 2014,

• Boehringer says faldaprevir does well in Asian hepatitis C patients

  Boehringer says faldaprevir does well in Asian hepatitis C patients. Trial success in patients from Korea, Japan and Taiwan. ... Boehringer Ingelheim's second-generation hepatitis C virus protease inhibitor faldaprevir achieved a viral cure rate of

• Boehringer moves interferon-free hep C regimen into phase III

  The combination of two of Boehringer's oral hepatitis C drugs - faldaprevir and BI 207127 - plus ribavirin achieved viral cure rate of up to 85 per cent after just 28 weeks' treatment ... Faldaprevir is a once-daily protease inhibitor while BI 207127 is

• J&J wins FDA panel backing for hepatitis C drug

  Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral cure rates and milder side